Non-Small-Cell Lung Cancer | Unmet Need | EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC | US/EU5 | 2023
Approximately 20% of Western patients with nonsquamous NSCLC present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive metastatic nonsquamous NSCLC patients is dominated by EGFR TKIs, most notably Tagrisso (AstraZeneca), there remains a strong need for drugs offering improved overall survival and less toxicity. Additional drugs targeting rare EGFR mutations, such as the 2021-approved Rybrevant (Janssen) and Exkivity (Takeda), are similarly needed. Acquired resistance to targeted therapies creates an additional need for novel treatments and optimization of treatment sequencing.
QUESTIONS ANSWERED
- Which attributes most influence prescribers’ decisions for EGFR mutation-positive metastatic nonsquamous NSCLC?
- How do key current therapies, such as EGFR TKIs, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for EGFR mutation-positive metastatic nonsquamous NSCLC?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 34 European medical oncologists fielded in May 2023.
Key companies: AstraZeneca, Boehringer Ingelheim, Pfizer, Johnson & Johnson, Roche / Genentech.
Key drugs: Tagrisso, Iressa, Tarceva, Gilotrif, Vizimpro, Rybrevant.
